Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-75 will be recruited. All will have an established radiological diagnosis of bronchiectasis (CT of the chest). Patients will have clinically significant bronchiectasis expectorating mucopurulent or purulent sputum when clinically stable with at least 2 chest infections per year.~Exclusion Criteria:~* current smokers or ex-smokers of less than 1 year; \>15 pack year history~* cystic fibrosis~* active allergic bronchopulmonary aspergillosis~* active tuberculosis~* poorly controlled asthma~* pregnancy or breast feeding~* known allergy to statins~* active malignancy~* chronic liver disease~* established cardiovascular or cerebrovascular disease~* statin use in the last year~* patients on long term oral macrolides due to the interaction with statin therapy patients chronically colonised with Pseudomonas aeruginosa (defined as two or more isolates of Pseudomonas aeruginosa whilst clinically stable in 6 months prior to the study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: ACTIVE_COMPARATOR): Atorvastatin 80mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).